玖龍紙業(02689.HK):2025財年股東應占盈利增加135.4%至17.67億元
格隆匯9月24日丨玖龍紙業(02689.HK)發佈公吿,截至2025年6月30日止年度,集團的銷量增加9.6%至約2150萬噸;收入增加約6.3%至人民幣632.405億元;毛利潤增加約26.9%至人民幣72.451億元;淨利潤增加約177.3%至人民幣22.017億元;公司權益持有人應占盈利增加約135.4%至人民幣17.671億元;每股基本盈利增加約137.5%至人民幣0.38元。
2025財政年度,毛利潤同比增加約26.9%,毛利率則由2024財政年度的9.6%增加至2025財政年度的約11.5%,主要由於原料成本的跌幅較產品售價的跌幅更大及更快所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.